clinical trial · NCT07146217
Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection
Bacterial InfectionsLikmez® (metronidazole) Oral Suspension
brief summary
This is an open-label, single-arm, pharmacokinetic and safety study of Likmez® in pediatric patients aged 12 months to \<4 years with anaerobic bacterial infection
started
Aug 1, 2025
primary completion
Jul 1, 2026
completion
Oct 1, 2026
last updated
Aug 28, 2025
official title
An Open-Label, Single-Arm, Pharmacokinetic and Safety Study of Likmez® (Metronidazole Oral Suspension) in Pediatric Patients Aged 12 Months to <4 Years With Anaerobic Bacterial Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol